News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

  • KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

  • KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

  • KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

  • KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

  • KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

  • KemPharm, Inc. Reports Third Quarter 2018 Results

  • KemPharm to Report Third Quarter 2018 Results

  • KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ® 

  • KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

  • KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

  • KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape